Neuland Laboratories (524558) Stock Overview
Engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 524558 from our risk checks.
524558 Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neuland Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹23,803.80 |
| 52 Week High | ₹24,235.05 |
| 52 Week Low | ₹11,500.00 |
| Beta | 0.30 |
| 1 Month Change | 3.71% |
| 3 Month Change | 38.58% |
| 1 Year Change | 52.97% |
| 3 Year Change | 568.55% |
| 5 Year Change | 1,336.78% |
| Change since IPO | 31,220.79% |
Recent News & Updates
Narrative Update • Aug 20
524558: Capacity Expansion And Transdermal CDMO Mandates Will Shape Measured Future Outlook
Analysts have raised their fair value estimate for Neuland Laboratories from ₹22,784.50 to ₹24,334.75, citing updated assumptions for revenue growth, profit margins and future P/E levels. What’s in the News for Neuland Laboratories Board meeting scheduled for 5 August 2026 at 10:00 IST to review unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 and to consider capacity expansion at Unit 1 in Telangana.Narrative Update • Aug 06
524558: Capacity Plans And Transdermal CDMO Work Will Shape Balanced Future Outlook
Analysts have raised their price target on Neuland Laboratories from ₹20,972 to ₹22,784.50, citing updated assumptions that include a slightly lower discount rate, moderated revenue growth expectations, and a higher profit margin outlook alongside a broadly steady future P/E. What’s in the News for Neuland Laboratories A board meeting is scheduled for August 5, 2026 at 10:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Recent updates
Narrative Update • Aug 20
524558: Capacity Expansion And Transdermal CDMO Mandates Will Shape Measured Future Outlook
Analysts have raised their fair value estimate for Neuland Laboratories from ₹22,784.50 to ₹24,334.75, citing updated assumptions for revenue growth, profit margins and future P/E levels. What’s in the News for Neuland Laboratories Board meeting scheduled for 5 August 2026 at 10:00 IST to review unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 and to consider capacity expansion at Unit 1 in Telangana.Narrative Update • Aug 06
524558: Capacity Plans And Transdermal CDMO Work Will Shape Balanced Future Outlook
Analysts have raised their price target on Neuland Laboratories from ₹20,972 to ₹22,784.50, citing updated assumptions that include a slightly lower discount rate, moderated revenue growth expectations, and a higher profit margin outlook alongside a broadly steady future P/E. What’s in the News for Neuland Laboratories A board meeting is scheduled for August 5, 2026 at 10:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Narrative Update • Jun 13
524558: New Leadership And Transdermal CDMO Work Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹20,972, with only marginal tweaks to long term growth, profit margin and future P/E assumptions. As a result, the overall price target remains unchanged.Narrative Update • May 30
524558: New CEO And CDMO Focus Will Support Future Upside Potential
Analysts now peg Neuland Laboratories' fair value at ₹20,972, compared with the previous ₹18,852.75, citing updates to long term revenue growth, profit margin assumptions, and a higher future P/E multiple in their models. What's in the News A board meeting is scheduled for May 12, 2026 at 14:15 IST to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for FY 2025-26, along with other matters (Key Developments).Narrative Update • May 12
524558: Leadership Transition And CDMO Focus Will Shape Balanced Future Potential
Analysts have trimmed their fair value estimate for Neuland Laboratories slightly from ₹18,865.25 to ₹18,852.75. This reflects small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E multiples.Narrative Update • Apr 20
524558: Leadership Transition And Peptide Collaboration Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25, reflecting unchanged views on discount rate, revenue growth, profit margin, and future P/E assumptions that underpin their price target rationale. What's in the News Neuland Laboratories plans a leadership transition, with Saharsh Davuluri set to become Chief Executive Officer from 01 April 2026.Narrative Update • Apr 04
524558: Phase 2 Peptide Design Progress Will Support Future Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹18,865.25, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. This signals that the latest review did not alter their core outlook on the stock.Narrative Update • Mar 20
524558: Phase 2 Peptide Progress And 2026 Board Meeting Will Support Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories steady at ₹18,865.25. This reflects unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E expectations.Narrative Update • Mar 05
524558: Peptide Partnership Progress And Upcoming Results Date Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Neuland Laboratories at ₹18,865.25 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. As a result, this narrative update focuses on reaffirmed conviction rather than a change in the price target.Narrative Update • Feb 19
524558: New R&D Center And Peptide Partnership Will Support Future Upside Potential
Analysts have revised their price target for Neuland Laboratories from ₹20,659 to ₹18,865, reflecting updates to their model that now factors in adjusted assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News LIR Life Sciences has started Project Phase 2 peptide design work with Neuland Laboratories, focusing on next generation cell penetrating peptides for its transdermal delivery platform, following completion of Phase 1 synthesis work (Product related announcement).Narrative Update • Feb 05
524558: New R&D Center Will Support Future Upside Potential
Analysts have kept their price target for Neuland Laboratories unchanged at ₹20,659, citing consistent assumptions on discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Board meeting scheduled for February 9, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Narrative Update • Jan 21
524558: New R&D Center And Peptide Partnership Will Drive Future Upside
Analysts have trimmed their fair value estimate for Neuland Laboratories from ₹20,884 to ₹20,659, citing slightly adjusted views on revenue growth, profit margins and future P/E assumptions while keeping the discount rate unchanged. What's in the News LIR Life Sciences Corp.Narrative Update • Jan 06
524558: New R&D Center Capex Will Support Future Upside Potential
Analysts have kept their fair value estimate for Neuland Laboratories unchanged at ₹20,884. This steady view is supported by consistent assumptions on discount rate, revenue growth, profit margin and future P/E.Narrative Update • Dec 15
524558: New R&D Center Will Drive Future Upside Potential
Narrative Update on Neuland Laboratories Analysts have modestly revised their price target on Neuland Laboratories with a slight adjustment that reflects largely unchanged assumptions around fair value at ₹20,884, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News The board will consider capital expenditure of INR 1,890 million for establishing a new Research and Development Center at the meeting scheduled on November 28, 2025 (Board Meeting).Narrative Update • Dec 01
524558: R&D Center and Leadership Changes Will Unlock Upside Potential
Analysts have maintained their price target for Neuland Laboratories at ₹20,884, citing consistent estimates for future revenue growth and profit margin projections. What's in the News A Board Meeting is scheduled for November 28, 2025 to approve and consider a capital expenditure of INR 1,890 million for setting up a Research & Development (R&D) Center.Narrative Update • Nov 17
524558: Executive Leadership Changes Will Drive Future Upside Potential
Analysts have raised their fair value estimate for Neuland Laboratories from ₹17,494.50 to ₹20,884.00. They cite updated assumptions about growth and profitability, despite modest adjustments to revenue growth and profit margin forecasts.Narrative Update • Nov 03
524558: Leadership Changes And Board Decisions Will Shape The Next Phase
Analysts have raised their price target for Neuland Laboratories from ₹16,375 to ₹17,494.50. This change reflects updated expectations based on modest adjustments in forecasted revenue growth, profit margin, and valuation multiples.Narrative Update • Sep 05
Manufacturing Expansion And Peptide Expertise Will Unlock Future Opportunities
Neuland Laboratories’ target price has been revised upward as a result of a marked increase in its forecast P/E ratio despite a significant decline in net profit margin, now reflecting a new consensus of ₹16,375. What's in the News Special/Extraordinary Shareholders Meeting to be conducted via postal ballot.
New Narrative • Feb 24
Ongoing Capacity Expansions In CDMO And Specialty GDS Set To Strengthen Future Prospects
New facilities and capacity expansion will drive revenue growth and improve operational efficiency by FY '26.Shareholder Returns
| 524558 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.9% | -0.4% | -0.6% |
| 1Y | 53.0% | 15.5% | -0.1% |
Return vs Industry: 524558 exceeded the Indian Pharmaceuticals industry which returned 15.5% over the past year.
Return vs Market: 524558 exceeded the Indian Market which returned -0.1% over the past year.
Price Volatility
| 524558 volatility | |
|---|---|
| 524558 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: 524558 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524558's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,183 | Davuluri Rao | www.neulandlabs.com |
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies.
Neuland Laboratories Limited Fundamentals Summary
| 524558 fundamental statistics | |
|---|---|
| Market cap | ₹298.30b |
| Earnings (TTM) | ₹4.98b |
| Revenue (TTM) | ₹23.72b |
61.4x
P/E Ratio12.9x
P/S RatioIs 524558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524558 income statement (TTM) | |
|---|---|
| Revenue | ₹23.72b |
| Cost of Revenue | ₹10.63b |
| Gross Profit | ₹13.09b |
| Other Expenses | ₹8.11b |
| Earnings | ₹4.98b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 387.98 |
| Gross Margin | 55.18% |
| Net Profit Margin | 20.99% |
| Debt/Equity Ratio | 16.1% |
How did 524558 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 11:44 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuland Laboratories Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Srivathsan Ramachandran | Avendus Spark |
| Kameswari V. S. Chavali | FirstCall Research |